Specific treatments for (pediatric) acute myeloid leukemia (AML) are lacking.
Standard treatments still include intensive myelosuppressive chemotherapy, which is unsatisfactory in terms of general toxicity, with the persistent risk of relapse due to the escape of quiescent leukemic cells to chemotherapy. Importantly, only 11 to 23 % of pediatric patients diagnosed with the most aggressive leukemia subtype harboring a known genetic rearrangement are designated as event-free survivors at 5 years.
Our invention relates to novel analogs of thioridazine, that lack a characteristic CNS toxicity of the parent molecule, for a targeted treatment of the most aggressive pediatric subtype of acute myeloid leukemia (t(6;11)AML featuring disease free survival at 5 years of only 11-23%).

TRL (Technology Readiness Level)

Lead Optimization/Preclinical

Inventors

Martina Pigazzi

Claudia Tregnago

Romeo Romagnoli

Download the brochure

Share this

Facebook
Twitter
Linkedin
Email

  • Bicyclic peptides for targeted therapy against cancer

    Since inhibitors based on small molecules and macromolecules are not selective and potent enough, new compounds, including bicyclic peptides, have been developed in recent years. Bicyclic peptides are new generation therapeutic molecules which exhibit properties typical of monoclonal antibodies (high...

  • Therapeutic factors for the treatment of PolyQ diseases

    The polyglutamine (polyQ) diseases are a group of neurodegenerative disorders caused by expanded cytosine-adenine-guanine (CAG) repeats encoding a long polyQ tract in the respective proteins. To date, at least nine polyQ disorders have been described, see bellow for a list....

  • CuRE – Copper complexes as novel anticancer agents

    Although platinum-based drugs, such as cisplatin, have achieved great success in cancer treatment and are presently enclosed in the majority of clinical protocols for the management of solid malignancies, their use are associated with significant drawbacks such as severe toxic...

Subscribe to newsletter

Follow the activities promoted by UniSMART Foundation